CSPI Comments for AHRQ Draft Systematic Review: Effects of Dietary Sodium and Potassium Intake on Chronic Disease Outcomes and Related Risk Factors

Tell FDA not to give potassium a bad name!

The report overall brings much‐needed clarity to the broad body of evidence on sodium and potassium but CSPI says it has limitations.

CSPI says the report would have reached stronger conclusions if it had excluded studies at high risk of bias. The group called on AHRQ to limit its review to studies at low risk of bias, even if the remaining, higher‐quality studies were few. At a minimum, AHRQ could have looked separately at the evidence from studies with a high vs. low risk of bias and based its conclusions on studies at low risk of bias.

View resource